Hybrid closed-loop systems (HCLS) and sensor-augmented pump (SAP) therapy are advanced technologies for type 1 diabetes management, yet their comparative effectiveness remains unclear. To address this gap, a study evaluated the impact of HCLS versus SAP on glycemic control, glucose variability, and time in range, involving approximately 1,000 participants. The study found that HCLS significantly improved glycemic outcomes compared with SAP therapy, with lower mean glucose levels by 2.0 mg/dL, reduced glucose variability (coefficient of variation and standard deviation CV and SD), and decreases in low blood glucose index (LBGI), high blood glucose index (HBGI), and glycated hemoglobin (HbA1c).
HCLS increased time in range by 8.8% and substantially reduced hyperglycemia, including time above 10 mmol/L by 7.8%, above 13.9 mmol/L by 3.63% and above 16.7 mmol/L by 0.88%. Improvements in…
